New Melotime melatonin study results from Nutriventia show healthy sleep pattern support
Nutriventia announced results from a recent study looking into how Melotime could possibly be used in promoting healthy sleep patterns.
Image | adobe.stock/Gorodenkoff
In a recent press release, Nutriventia revealed new pharmacokinetic study results in regard to their Melotime sustained-release melatonin product. The study investigated Melotime’s potential role in healthy sleep habits.
In the press release, Dr. Shefali Thanawala, head of Medical Science and Research, said that the, “the study demonstrates the unique benefits of Nutriventia's advanced delivery technology, which addresses common limitations of traditional melatonin supplements.”
The study utilized a research pool of 16 healthy men and women between the ages of 18 to 45 years old. Participants were given 5 mg of Melotime or 5 mg of an immediate-release formulation which was then proceeded by a seven-day washout period. Additionally, participants were put into a windowless room that used standardized lighting. The study mentioned that, “Standardized lighting conditions were maintained in the clinical phase unit to suppress the production of endogenous melatonin. This standardization included housing the participants in a windowless room on the dosing day and was maintained throughout the entire blood sampling period in both the treatment periods with all light readings between 500 to 600 Lux.”1
Light levels were measured via a Luxmeter four times throughout the day. Researchers analyzed the maximum concentration (Cmax), time it took to reach Cmax, area under the curve, and elimination of half-life. Data was collected during two periods. Researchers took a total of 20 blood samples from each participant. Plasma was separated from the blood and then researchers utilized ultra-high performance liquid chromatography-mass spectroscopy (UHPLC-MS/MS) to quantify the concentration of melatonin.1
Data revealed that Melotime lengthened the release of melatonin and also prolonged the half-life when compared to the immediate-release formulation.
“Melotime's sustained-release design is beneficial for bioactives like melatonin, which traditionally require repeated doses due to their short half-life,” said Thanawala in the press release. “By maintaining melatonin levels over an extended period, Melotime can provide more convenient and effective support for managing sleep cycles naturally.”
Rajat Shah, the company's director added that "by avoiding sharp peaks in melatonin concentration, which are common with immediate-release formulations, the study demonstrates that Melotime’s smooth, controlled release helps ensure melatonin levels remain balanced, especially during critical early morning hours, promoting safer and more consistent support for healthy sleep patterns."
Reference
- Thanawala, S.; Abiraamasundari, R.; Shah, R. Comparative Pharmacokinetics of Sustained-Release versus Immediate-Release Melatonin Capsules in Fasting Healthy Adults: A Randomized, Open-Label, Cross-Over Study. Pharmaceutics 2024, 16, 1248. https://doi.org/10.3390/pharmaceutics16101248
